biotech / news / / Free Press Journal
The company has signed an agreement to acquire select product assets from Sanofi.
Gujarat Themis Biosyn is acquiring 13 Sanofi brands in anti-infectives and tuberculosis for €158 million.
KEY POINTS
- The deal excludes manufacturing facilities or employees, streamlining integration and reducing complexity.
- The acquired brands generated €62 million in FY2025 revenue, with 70% from retail channels.
- This acquisition gives Gujarat Themis immediate presence in 55 countries, mostly in Europe, the Middle East, and Africa.
- The company plans to reactivate dormant marketing authorizations and expand in high tuberculosis burden markets.
COMPANIES
Summarized by Newsio from Free Press Journal. How we summarize →